UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,227	05/18/2005	Igor Yu Galaev	PU0242	2606

22840 7590 06/28/2007

GE HEALTHCARE BIO-SCIENCES CORP.
PATENT DEPARTMENT
800 CENTENNIAL AVENUE
PISCATAWAY, NJ 08855

EXAMINER	
HENRY, MICHAEL C	

ART UNIT	PAPER NUMBER
1623	

MAIL DATE	DELIVERY MODE
06/28/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/517,227	GALAEV ET AL.	
	Examiner	Art Unit	
	Michael C. Henry	1623	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on _____.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) 1-17 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) 1-17 is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☒ All b)☐ Some * c)☐ None of:

1.☒ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 12/07/04.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

Claims 1-17 are pending in application

Priority

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Information Disclosure Statement

The information disclosure statement filed complies with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609. It has been placed in the application file and the information referred to therein has been considered as to the merits.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Snoke et al. (US 4,055,469) in view of Izumrudov et al. (Biopolymers (nucleic acid sciences), Vol. 52, 94-108 (1999).

In claim 1, applicant claims a method of isolating a desired nucleic acid from a biological solution, that may contain other species including nucleic acids, proteins, other high molecular weight compounds, salts and other low-molecular weight substances, which method comprises selectively precipitating the desired nucleic acid, while leaving the other species in solution, by adding a polycationic precipitating agent to the solution and allowing it to form an insoluble

complex with said desired nucleic acid, wherein the precipitating agent is a highly charged linear polymer that includes quaternary amino groups, and further wherein the precipitating agent is added to the solution in the presence of a salt, wherein the amount of said precipitating agent is sufficient to attain a charge ratio [+] / [-] between the precipitating agent and nucleic acid of ≥ about 0.5 during the precipitation. Claims 2, 8-10 are drawn to the method of claim 1, wherein the precipitating agent includes specific positive charges, specific ratio of polymer molecular wt to polymer charge in the precipitating agent, precipitating agent of specific positive charge, specific precipitating agents including poly(N',N'-dimethyldiallylammonium) chloride, ionene bromide and poly(N-alkyl-4-vinylpyridinium). Claim 3 is drawn to said method further comprising a step of estimating the number of negative charges in the biological solution before addition of the precipitating agent. Claims 4-7 are drawn to said method involving specific nucleic acid and specific biological solutions. Claim 11 is drawn to said method involving the controlling of salt solution during the addition of the precipitating agent to allow quantitative selective precipitation of nucleic acid/polycation complex. Claim 12 is drawn to the method of claim 1, further comprising recovering nucleic acid from the precipitate formed by separating the precipitate from solution and subsequent dissolution and/or destruction of the complex. Claims 13-14 are drawn to said method involving the dissolution or destruction of the polyelectrolyte complex by addition of salt and of salt of specific concentration depending on the charge ratio and salt nature. Claims 16-17 are drawn to said method comprising first and second isolations of nucleic acid from the biological solution and isolating nucleic acids subjected to modification reactions.

Snoke et al. disclose a method of isolating a desired nucleic acid from a biological solution, that may contain other species including proteins, which method comprises selectively precipitating the desired nucleic acid, while leaving the other species in solution, by adding a polycationic precipitating agent to the solution and wherein the precipitating agent is a highly charged linear polymer that includes quaternary amino groups, and further wherein the precipitating agent is added to the solution in the presence of a salt (see abstract, example 6 and claims).

The difference between applicant's claimed method and the method taught by Snoke et al. is that Snoke et al. do not disclose the formation of an insoluble complex of the nucleic acid and the precipitating agent nor a need for the amount of precipitating agent to be sufficient to attain a charge ratio [+] / [-] between the precipitating agent and nucleic acid of ≥about 0.5 during the precipitation.

Izumrudov et al. disclose that polycationic agents or polycationic polymers poly(N',N'-dimethyldiallylammonium) chloride, ionene bromide and poly(N-alkyl-4-vinylpyridinium) bind to DNA (nucleic acid) and forms a complex and that the stability of the complexes can be controlled by varying e.g. the salt concentration (see page 104, paragraph 3 to page end of page 10). Furthermore, Izumrudov et al. disclose that the addition of salt can dissolve or destruct the complex (see abstract).

It would have been obvious to one having ordinary skill in the art, at the time the claimed invention was made to have used the method of Snoke et al. to isolate a desired nucleic acid from a biological solution comprising selectively precipitating the desired nucleic acid, by adding a polycationic precipitating agent to the solution in the presence of salt and in view of Izumrudov

et al. to allow the formation of an insoluble complex of the precipitating agent with said desired nucleic acid and to determine the amount of precipitating agent such as in terms of the charge ratio of precipitating agent to nucleic acid that is required to produce a complex as taught by Izumrudov et al. which can be separated by adjusting the salt concentration.

One having ordinary skill in the art would have been motivated to use the method of Snoke et al. to isolate a desired nucleic acid from a biological solution comprising selectively precipitating the desired nucleic acid, by adding a polycationic precipitating agent to the solution in the presence of salt and in view of Izumrudov et al. to allow the formation of an insoluble complex of the precipitating agent with said desired nucleic acid and to determine the amount of precipitating agent such as in terms of the charge ratio of precipitating agent to nucleic acid that is required to produce a complex as taught by Izumrudov et al. which can be separated by adjusting the salt concentration. In addition, it should be noted that a substance such as the said complex precipitates from solution when the net charge is zero thus a skilled artisan would be motivated to determine the limiting amount of precipitating agent that is required to form the said complex and to ensure precipitation. Furthermore, it should be noted that it is obvious to repeat the addition of precipitating agent to the remaining biological solution so as to precipitate, obtain or isolate a greater yield or quantity of said nucleic acid.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Henry whose telephone number is 571-272-0652. The examiner can normally be reached on 8.30am-5pm; Mon-Fri. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be

reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael C. Henry

6/25/07

Shaojia Anna Jiang, Ph.D.
Supervisory Patent Examiner
Art Unit 1623

June 23, 2007.